Lumexa Imaging Holdings, Inc. LMRI R2KPHARMA
Company Overview
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.
Recent Developments
- Dec 2025 Revenue of $1.02B (+7.8% YoY); net profit $-47.10M.
- Trailing 12 Months Year-on-year growth — revenue +5.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.55% |
| 1 Year: | 5.10% |
Stock Price Performance
| 1 Year: | -37.04% |
| 6 Months: | +21.46% |
| 3 Months: | +5.52% |
| 1 Month: | +18.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 37.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LMRI Lumexa Imaging Holdings, Inc. R2KPHARMA | 11.66 | -40.21 | $1.12B | 0.00% | 1.69% | -8.04% | 4.55% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 248.03M | 245.00M | 267.73M | 252.54M |
| Cost of Revenue | 226.46M | 208.40M | 225.62M | 217.75M |
| Gross Profit | 21.57M | 36.60M | 42.12M | 34.78M |
| Operating Expenses | 29.97M | 26.54M | 49.59M | 30.26M |
| Operating Income | -8.40M | 10.06M | -7.47M | 4.53M |
| EBITDA | 28.94M | 38.33M | 19.00M | 33.29M |
| Interest Expense | 31.39M | 29.85M | 28.02M | 16.33M |
| Pretax Income | -16.03M | -4.31M | -25.26M | 3.08M |
| Tax Provision | 9.03M | 3.38M | 3.43M | 1.36M |
| Net Income | -25.06M | -7.69M | -28.69M | 1.72M |
| Diluted EPS | - | -0.08 | -0.38 | 0.02 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 935.92M | 948.87M | 1.02B |
| Cost of Revenue | 836.96M | 852.61M | 865.52M |
| Gross Profit | 98.97M | 96.26M | 157.56M |
| Operating Expenses | 111.80M | 112.53M | 130.83M |
| Operating Income | -12.83M | -16.26M | 26.73M |
| EBITDA | 94.51M | 113.96M | 141.71M |
| Interest Expense | 141.69M | 136.03M | 118.54M |
| Pretax Income | -119.25M | -79.19M | -32.22M |
| Tax Provision | 2.98M | 14.91M | 14.88M |
| Net Income | -122.23M | -94.10M | -47.10M |
| Diluted EPS | -1.76 | -1.35 | -0.66 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 1.67B | 1.67B | 1.76B |
| Current Assets | 166.77M | 172.52M | 227.26M |
| Cash & Equivalents | 20.19M | 26.13M | 58.83M |
| Inventory | - | - | - |
| Receivables | 124.12M | 130.35M | 131.84M |
| Total Liabilities | 1.47B | 1.51B | 1.18B |
| Current Liabilities | 161.12M | 173.66M | 179.19M |
| Long Term Debt | 1.18B | 1.19B | 819.03M |
| Total Debt | 1.30B | 1.31B | 962.50M |
| Total Equity | 198.43M | 161.65M | 586.12M |
| Shares Outstanding | 94.57M | 94.57M | 96.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 37.51M | 40.73M | 17.07M |
| Investing Cash Flow | -29.66M | -22.28M | -20.96M |
| Financing Cash Flow | -8.77M | -12.50M | 36.58M |
| Capital Expenditure | -24.01M | -27.77M | -23.48M |
| Free Cash Flow | 13.51M | 12.95M | -6.40M |
| Net Change in Cash | -912.00K | 5.95M | 32.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 10.6% | 10.1% | 15.4% |
| Operating Margin % | -1.4% | -1.7% | 2.6% |
| Net Margin % | -13.1% | -9.9% | -4.6% |
| ROE % | -61.6% | -58.2% | -8.0% |
| ROCE % | -0.8% | -1.1% | 1.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brown Advisory Inc. | 6.01% | 5.78M | $60.90M |
| 2 | Massachusetts Financial Services Co. | 3.59% | 3.45M | $36.40M |
| 3 | Think Investments LP | 2.66% | 2.56M | $26.98M |
| 4 | Jupiter Topco LLC | 2.24% | 2.15M | $22.68M |
| 5 | Blackrock Inc. | 1.46% | 1.40M | $14.74M |
| 6 | JPMORGAN CHASE & CO | 1.20% | 1.15M | $12.17M |
| 7 | Vanguard Capital Management LLC | 1.11% | 1.07M | $11.28M |
| 8 | Goldman Sachs Group Inc | 0.84% | 807.43K | $8.51M |
| 9 | Royce & Associates LP | 0.82% | 789.04K | $8.32M |
| 10 | Schonfeld Strategic Advisors Llc | 0.80% | 768.89K | $8.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LMRI
Lumexa Imaging Holdings, Inc. (LMRI) - What Are Investment Firms Thinking About This Stock? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOakdjWXZNdDcwcWJUQmNqbm9qRE5QMmpLNmR2eUl6ZnVXbFV5QXp2eml5ejlUTmFBOFZGS29IN2pXdzg1emhQcmJ2aXpueXYxbWQ0X2U5bVV2UnBOa25QbzU5MkYyX2tIVl80T0Uzd1V0T1B4NnhUMDU5T3VoWUowOVl1YVRlTmM3MElMbG…
Lumexa Imaging Holdings (LMRI) Could Be 36% Below Fair Value On Its Imaging Growth Story - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxON2lVU0lBNThMNjk3NVROOEhPMjh5QjFWdVZPTU5pZm9oR09UQ1haOWRlVS1QWVBPN2NvUkc0dVd4cEJ0cnpXV240WS1UQkl4cDhZUmlSYU82NGZWVkg4Q1lSV3pJbGF4YWxzYTFpTE1ybllPOUZOaHdmSWJmQmZXXzJBRTV3UGFCckZDWW…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1EWU1WZXhiTnpheEpCWDNPaWREenNZV2t2cnJfbEgwdWpIYUgyTzZ2RGdGOE9CVlpLSDE5dlQzRTd4LVZuNHpRWERWa0ZCVnlX?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Lumexa acquires imaging center as part of new joint venture with UPMC - Radiology Business
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNUVhOTFNibUwtMDhaZnNmNXoxaDdCLVdvUVBOUlJlXzBFeXFXTzdZRHdOMkRNRHpFUmVzb01MZmFTd21YZzZhREtOQVZMQ1VFeENJRWRubVVTOUlKREY3QVFHcUlMdl9vNlBGUllLdFY4SUlUZUZnYUdIZDdzbzEzRWFPRzVpMm9OaW9ERV…
LMRI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBYUm5zaVJVLU1oXzBjMjdKYkxzRDNPZTJiWHFjMDNCOWNCTzVFV2ZJeHk4TkZwbGFJa2g5M2JnSUY0eW1ncXNmbE1rZU9INktCWnRMcU54TERSaTZaMUNCTUN1S1FjZDFkSjdQcTRyWUo1WWNNYWppMU1B?oc=5" target="_blank">LMR…
Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPZHJNN2diNl9LR2s5VFhZZHlQWG10dGhtQTNFdzRCMGZ5V1RsNTEzV285OVJxcHplNjVKLXFPcFdoLTU4WTZEQVhSdXlPR0xGek40X2daUjNBTlZJSDFFNV9zTGhBT2QzelJpYmlzUUt6ektXbE15SE9BbzFrQlFkSHBIVzNfcGRQRnY3YU…
LMRI — Frequently Asked Questions
What is the current share price of Lumexa Imaging Holdings, Inc. (LMRI)?
As of 2026-10-23 16:27 PDT, Lumexa Imaging Holdings, Inc. (LMRI) trades at $11.66 on NasdaqGS. Its 52-week range is $6.77 to $18.53.
What is the market capitalisation of LMRI?
Lumexa Imaging Holdings, Inc. (LMRI) has a market capitalisation of $1.12B on NasdaqGS.
What is the P/E ratio of LMRI?
LMRI trades at a trailing price-to-earnings (P/E) ratio of -40.21. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.73.
What is the return on equity (ROE) of LMRI?
LMRI has a return on equity (ROE) of -8.04%. Its return on capital employed (ROCE) is 1.69%.
Is LMRI a good stock to buy?
This page provides a data-driven analysis of Lumexa Imaging Holdings, Inc. (LMRI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.